Immunocore achieves 540-patient target enrollment in Phase 3 TEBE-AM trial of tebentafusp in post-PD1 melanoma

Immunocore Holdings plc

TEBE-AM enrolled 540 patients; randomized Phase 3 trial of tebentafusp ± pembrolizumab vs investigator's choice in HLA-A*02:01+ advanced melanoma.
Primary endpoint overall survival; topline data expected as early as end of 2026.
Trial targets previously treated post-PD1 advanced melanoma; potential addressable population ~4,000 patients in US/EU.
Registrational trial; enrollment milestone supports KIMMTRAK expansion beyond first-line uveal melanoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.